Feature | February 22, 2013| Dave Fornell

FDA Approves Use of Common Abbott Devices to Treat for Coronary CTOs

Additional indications allow its everyday guidewires and balloons to be used in chronic total occlusions (CTOs)

balloon, CTO

Abbott's Mini-Trek balloon dilatation catheter.

guidewire, CTO

Abbott'e HT Pilot guidewire.

February 22, 2013 — Physicians have new tools for treating coronary chronic total occlusions (CTOs) after Abbott received U.S. Food and Drug Administration (FDA) approval this week for guidewires and balloon dilation catheters for treatment of CTOs. Abbott is the only company with FDA approvals of its everyday products for treatment of CTOs.

The FDA approval is for Abbott's HT Progress and HT Pilot guidewires and Mini-Trek balloon dilatation catheter products.

Treatment of CTOs, a 100 percent blockage in the artery, continues to be a controversial topic among cardiac specialists, though estimates indicate that 15 to 20 percent of patients undergoing coronary angiography have a CTO. While some physicians believe they are benign, others believe that CTOs are a slow, silent killer. In addition, treating CTOs with minimally invasive methods is not easy. Up until now, only a handful of specialty CTO products were approved to tackle these lesions.

While the recommended treatment for CTOs varies widely among doctors, many say coronary CTOs offer a potential growth area for patient volume in cath labs. Clinical evidence supports the treatment of CTOs if good procedural outcomes can be obtained. Patients with CTOs can experience significant improvements in quality of life if blood flow is restored to the vessel.

Clearly navigating CTOs can be difficult under 2-D angiography, which only shows a lumengram in the parts of the vessel that are not blocked. The controversy over treating CTOs often involves the guesswork involved when attempting to push wires through the occlusion without piercing the wall of the artery. However, recent advances in 3-D rotational angiography and fusion imaging with these images or computed tomography (CT) or magnetic resonance imaging (MRI) 3-D vessel reconstructions overlaid on live fluoroscopy are expected to greatly aid these types of procedures.

For more information: www.abbottvascular.com





Related Content

Tryton Side Branch Stent, clinical trial results, Catheterization and Cardiovascular Interventions

Tryton Side Branch Stent image courtesy of Tryton Medical

News | Stents Bifurcation| October 02, 2015
October 2, 2015 — Tryton Medical Inc.
Brilinta, 60 mg dose available, U.S. pharmacies
Technology | Antiplatelet and Anticoagulation Therapies| October 02, 2015
AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015,...
Intact Vascular, TOBA II study, Tack Endovascular System

Image courtesy of Intact Vascular

News | Peripheral Arterial Disease (PAD)| October 01, 2015
Intact Vascular Inc. announced the U.S. Food and Drug Administration has granted conditional approval for a U.S. and...
Cook Medical, Zilver PTX, Japan PMS study, CIRSE 2015, two-year results

Image courtesy of Cook Medical

News | Stents Peripheral| October 01, 2015
Kimihiko Kichikawa, M.D., department of radiology at Nara Medical University in Japan, reported two-year results of the...
Stentys, CE Mark for self-apposing stent, lower limb artery disease, below-the-knee arteries, critical limb ischemia, PES BTK-70 trial

Image courtesy of Stentys

News | Stents Peripheral| October 01, 2015
Stentys announced that the company’s drug-eluting stent received CE Mark for treatment of below-the-knee (BTK) arteries...
raysafe, i2, staff dose monitoring
News | Radiation Dose Management| October 01, 2015
October 1,2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and
News | Cath Lab| September 29, 2015
The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device...
News | Antiplatelet and Anticoagulation Therapies| September 25, 2015
The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety...
CeloNova BioSciences, Cobra PzF coronary stent system, second randomized trial, COBRA-REDUCE

Cobra PzF coronary stent system image courtesy of CeloNova BioSciences Inc.

News | Stents| September 23, 2015
CeloNova BioSciences Inc. announced that it has received conditional approval to start an investigational device...
Hansen Medical, CIRSE 2015, Magellan robotic catheter, cath lab, radiation safety, embolization procedures

Magellan Robotic System image courtesy of Hansen Medical Inc.

News | Interventional Radiology| September 22, 2015
Hansen Medical Inc. announced it will exhibit its Magellan robotic system at the Cardiovascular and Interventional...
Overlay Init